Manuel Dómine: Management and treatment of adverse events using lorlatinib in ALK-positive NSCLC

Manuel Dómine, Associate Head Oncology at Jiménez Díaz Foundation, shared a post on X about a recent paper by Edurne Arriola et al. titled “Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer” published in Clinical Drug Investigation.

Authors: Edurne Arriola, Javier de Castro, Rosario García-Campelo, Beatriz Bernárdez, Reyes Bernabé, Jordi Bruna, Manuel Dómine, Dolores Isla, Óscar Juan-Vidal, Teresa López-Fernández, Ernest Nadal, Delvys Rodríguez-Abreu, María Vares, Úrsula Asensio, Luis F. García, Enriqueta Felip.

“Recently published, a guideline for the management and treatment of the most relevant adverse events using lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts.”

Source: Manuel Dómine/X